Clinical Trial Update: Capecitabine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating capecitabine for recurrent ovarian cancer, fallopian tube cancer, or primary peritoneal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Capecitabine (Xeloda) (Capecitabine)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Fallopian Tube Cancer, Ovarian Cancer | Phase 2 | Status: COMPLETED